PT  - JOURNAL ARTICLE
AU  - GOMEZ-FLORES, RICARDO
AU  - CABALLERO-HERNANDEZ, DIANA
AU  - TAMEZ-GUERRA, REYES
AU  - RODRIGUEZ-PADILLA, CRISTINA
AU  - TAMEZ-GUERRA, PATRICIA
AU  - RICE, KENNER C.
AU  - HICKS, MARY E.
AU  - WEBER, RICHARD J.
TI  - Increased Survival of Tumor-bearing Mice by the Delta Opioid SNC 80
DP  - 2005 Nov 01
TA  - Anticancer Research
PG  - 4563--4567
VI  - 25
IP  - 6C
4099  - http://ar.iiarjournals.org/content/25/6C/4563.short
4100  - http://ar.iiarjournals.org/content/25/6C/4563.full
SO  - Anticancer Res2005 Nov 01; 25
AB  - Opioids represent a major source of relief from pain. However, opioid abuse may cause immunosuppression and cancer. We have recently reported results on novel non-peptidic delta- and mu-selective opioids that induced immunopotentiation of T cell and macrophage functions in vitro and ex vivo. In the present study, the effects of the delta-opioid receptor agonist and potent analgesic (+)-4-((alpha R)-alpha-((2S, 5R)-4-allyl-2, 5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-N, N-diethyl-benzamide (SNC80) on in vitro and in vivo tumor cell growth were investigated using the L5178Y-R murine model. SNC80 marginally, but significantly (p<0.05), inhibited (up to 14%) the in vitro growth of L5178Y-R tumor cells. However, in vivo intratumor administration of SNC80 (2 and 4 mg/kg) reduced up to 60% L5178Y-R tumor-bearing Balb/c mice death, and significantly (p<0.05) reduced tumor weights (up to 73% reduction) in these animals. This study may support the evaluation of SNC80 in preclinical and clinical studies. Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved